| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR090 |
| Uniprot No | P07614 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-350aa |
| 氨基酸序列 | MNTRTDVTNDNIDKNPTKRGDKNIPGRNERFNDQNRFNNDIPKPKPRLQPNQPPKQDNKCREENGDFINIRLCAYEKEYCNDGYLSPAYYMLKQVDDEEMSCWSELSSLVRSRKAVGFPLLKAAKRISHGSMLYFEQFKNSKVVRLTPQVKCLNDTVIFQTVVILYSMYKRGIYSNEFCFDLVSIPRTNIVFSVNQLMFNICTDILVVLSICGNRLYRTNLPQSCYLNFIHGHETIARRGYEHSNYFFEWLIKNHISLLTKQTMDILKVKKKYAIGAPVNRLLEPGTLVYVPKEDYYFIGISLTDVSISDNVRVLFSTDGIVLEIEDFNIKHLFMAGEMFVRSQSSTIIV |
| 预测分子量 | 42.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR090重组蛋白的参考文献示例(注：由于VACWR090相关研究较为专业且可能非公开高频内容，以下为模拟示例，建议通过学术数据库核实具体文献)：
1. **文献名称**: *Expression and Purification of Recombinant VACWR090 Protein from Vaccinia Virus*
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌系统中表达并纯化了VACWR090重组蛋白，通过质谱和Western blot验证其正确性，为后续功能研究奠定基础。
2. **文献名称**: *Structural Characterization of VACWR090 and Its Role in Viral Assembly*
**作者**: Zhang L, et al.
**摘要**: 利用X射线晶体学解析了VACWR090蛋白的三维结构，发现其与病毒颗粒组装相关，敲除实验表明该蛋白缺失影响痘苗病毒复制效率。
3. **文献名称**: *Immunogenicity of VACWR090 Recombinant Protein in Animal Models*
**作者**: Lee C, et al.
**摘要**: 在小鼠模型中评估VACWR090重组蛋白的免疫原性，结果显示其可诱导特异性抗体及T细胞应答，提示其作为疫苗候选抗原的潜力。
4. **文献名称**: *Comparative Analysis of VACWR090 Homologs in Poxviruses*
**作者**: Garcia R, et al.
**摘要**: 通过比对痘病毒科成员中VACWR090同源蛋白的序列和功能，揭示其在病毒进化中的保守性及可能的宿主互作机制。
**注意**：以上文献信息为模拟生成，实际研究需通过PubMed、Web of Science等平台以“VACWR090 recombinant protein”或“VACWR090 vaccinia”为关键词检索最新成果。
VACWR090 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. The vaccinia virus, notably the Western Reserve (WR) strain, has been extensively studied due to its historical role as the live vaccine used in smallpox eradication. VACWR090 corresponds to the viral gene *VACWR090* (also annotated as *C9L* in some strains), which encodes a protein involved in modulating host immune responses. This gene is conserved across orthopoxviruses and is classified as a virulence factor, contributing to viral evasion of host defenses.
The VACWR090 protein is expressed during the early phase of viral infection and functions as an immunomodulator. It interacts with host signaling pathways, particularly those related to the nuclear factor kappa B (NF-κB) and interferon (IFN) systems, which are critical for antiviral immunity. By inhibiting these pathways, VACWR090 suppresses pro-inflammatory cytokine production and attenuates the host’s innate immune response, facilitating viral replication and spread. Structurally, the protein contains conserved domains characteristic of poxviral host range factors, including a putative transmembrane region and motifs associated with protein-protein interactions.
Recombinant VACWR090 is engineered for research applications, such as elucidating poxviral pathogenesis or screening antiviral compounds. Its production typically involves expression in bacterial or mammalian systems, followed by purification to study biochemical properties or antigenicity. Additionally, VACWR090 has been explored in vaccine development, either as a component of subunit vaccines or a target for neutralizing antibodies. Studies using knockout mutants have highlighted its importance in viral fitness *in vivo*, making it a potential candidate for attenuated vaccine design. Overall, VACWR090 serves as a valuable tool for understanding poxvirus-host interactions and advancing therapeutic strategies against poxviral infections.
×
